Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | RAD52 | P43351 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 4/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | BACE1 | P56817 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL609241 | 0.86 | MEN1 (0.64) | LMNAGAAMAPTMEN1KMT2A | |
| SCHEMBL6815269 | 0.85 | POLB (0.84) | LMNAGAAMAPTMEN1KMT2A | |
| SCHEMBL610302 | 0.84 | MEN1 (0.67) | LMNAGAAMAPTMEN1KMT2A | |
| SCHEMBL607881 | 0.84 | LMNA (1.00) | LMNAGAAMAPTMEN1KMT2A | |
| SCHEMBL607287 | 0.83 | MEN1 (0.72) | LMNAGAAMAPTMEN1KMT2A | |
| SCHEMBL606733 | 0.81 | MEN1 (0.87) | LMNAGAAMAPTMEN1KMT2A | |
| Fumaric Acid SCHEMBL16026525 | 0.77 | MEN1 (0.72) | LMNAGAAMAPTMEN1KMT2A | |
| SCHEMBL5026936 | 0.77 | MEN1 (0.72) | LMNAGAAMAPTMEN1KMT2A | |
| Fumaric Acid SCHEMBL16026522 | 0.77 | MEN1 (0.72) | LMNAGAAMAPTMEN1KMT2A | |
| SCHEMBL7653795 | 0.77 | SIGMAR1 (0.52) | MAPTTSHRSIGMAR1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237887-B1 | 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS | SERONO LAB (CH) | 2008-06-04 | — | — | EP | claimed |
| EP-1094063-A1 | 9-(Piperazinylalkyl)carbazoles as Bax-modulators | Applied Research Systems ARS Holding N.V. (AN) | 2001-04-25 | — | — | EP | claimed |
| US-8410110-B2 | 9-(piperazinylalkyl) carbazoles as Bax-modulators | MERCK SERONO SA (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20120040933-A1 | 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2012-02-16 | — | — | US | disclosed |
| US-8053436-B1 | 9-(piperazinylalkyl) carbazoles as bax-modulators | MERCK SERONO SA (CH) | 2011-11-08 | — | — | US | disclosed |
| EP-1237887-B1 | 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS | SERONO LAB (CH) | 2008-06-04 | — | — | EP | disclosed |
| EP-1094063-A1 | 9-(Piperazinylalkyl)carbazoles as Bax-modulators | Applied Research Systems ARS Holding N.V. (AN) | 2001-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040933-A1 | 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS | BCL2, BAX, BAD | LMNA 55/4885GAA 926/4885MAPT 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.